Suppr超能文献

TPA 诱导的 p21 表达通过一种不依赖 p53 的机制增强人乳腺癌细胞的 G2/M 期阻滞。

TPA-induced p21 expression augments G2/M arrest through a p53-independent mechanism in human breast cancer cells.

机构信息

Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, Republic of Korea.

出版信息

Oncol Rep. 2012 Feb;27(2):517-22. doi: 10.3892/or.2011.1511. Epub 2011 Oct 20.

Abstract

The tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), has a differential role on the regulation of the cell cycle in a variety of tumor cells. The mechanism between TPA and the cell cycle in breast cancer is not fully understood. Therefore, we investigated the regulatory mechanism of TPA on control of the cell cycle of breast cancer cells. Our results showed that TPA increased the level of p21 expression in MCF-7 cells with wild-type p53 and MDA-MB-231 cells with mutant p53 in a dose-dependent manner. In contrast, TPA decreased the expression of p53 in MCF-7 cells, but did not affect MDA-MB-231 cells. We next examined the regulatory mechanism of TPA on p21 and p53 expression. Our results showed that the TPA-induced up-regulation of p21 and down-regulation of p53 was reversed by UO126 (a MEK1/2 inhibitor), but not by SP600125 (a JNK inhibitor) or SB203580 (a p38 inhibitor), although TPA increased the phosphorylation of ERK and JNK in MCF-7 cells. In addition, the TPA-induced arrest of the G2/M phase was also recovered by UO126 treatment. To confirm the expression of p21 through the MEK/ERK pathway, cells were transfected with constitutively active (CA)-MEK adenovirus. Our results showed that the expression of p21 was significantly increased by CA-MEK overexpression. Taken together, we suggest that TPA reciprocally regulates the level of p21 and p53 expression via a MEK/ERK-dependent pathway. The up-regulation of p21 in response to TPA is mediated through a p53-independent mechanism in breast cancer cells.

摘要

肿瘤促进剂 12-O-十四烷酰佛波醇-13-乙酸酯(TPA)在多种肿瘤细胞的细胞周期调控中具有不同的作用。TPA 与乳腺癌细胞周期之间的机制尚未完全阐明。因此,我们研究了 TPA 对乳腺癌细胞周期调控的调节机制。

我们的结果表明,TPA 以剂量依赖性方式增加 MCF-7 细胞(野生型 p53)和 MDA-MB-231 细胞(突变型 p53)中 p21 的表达水平。相反,TPA 降低了 MCF-7 细胞中的 p53 表达,但对 MDA-MB-231 细胞没有影响。

我们接下来研究了 TPA 对 p21 和 p53 表达的调节机制。我们的结果表明,TPA 诱导的 p21 上调和 p53 下调被 UO126(MEK1/2 抑制剂)逆转,但不被 SP600125(JNK 抑制剂)或 SB203580(p38 抑制剂)逆转,尽管 TPA 增加了 MCF-7 细胞中 ERK 和 JNK 的磷酸化。此外,UO126 处理还恢复了 TPA 诱导的 G2/M 期阻滞。

为了确认 p21 通过 MEK/ERK 途径的表达,用组成型激活(CA)-MEK 腺病毒转染细胞。我们的结果表明,CA-MEK 过表达显著增加了 p21 的表达。

综上所述,我们认为 TPA 通过 MEK/ERK 依赖性途径相互调节 p21 和 p53 表达水平。TPA 上调 p21 是通过乳腺癌细胞中 p53 独立的机制介导的。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验